Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study

REFERENCES

• Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5:185–6.
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic rheumatic conditions. Geneva: World Health Organization; 2009.
   Google Scholar
• Whalley D, McKenna SP, De Jong Z, Van Der Heijde D. Quality of life in rheumatoid arthritis. Br J Rheumatol. 1997;36:884–8.
   Google Scholar
• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473–88.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleisch-mann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr Rheum. 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breed-veld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.
   Google Scholar
• Criscione LG, St Clair EW. Tumor necrosis factor-alpha antag-onists for the treatment of rheumatic diseases. Curr Opin Rheu-matol. 2002;14:204–11.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349: 1907–15.
   Google Scholar
• Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford). 2008;47:1461–8.
   PubMed Web of Science ®Google Scholar
• Close DR. Matrix metalloproteinase inhibitors in rheumatic dis-eases. Ann Rheum Dis. 2001;60(3):iii62–67.
   Google Scholar
• Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheuma-toid arthritis: a pilot, dose-finding, double-blind, placebo-con-trolled clinical trial evaluating CTLA-41g and LEA29Y eighty-five days after the first infusion. Arthr Rheum. 2002;46: 1470–9.
   Google Scholar
• Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud MC, et al. Effects of abatacept in patients with metho-trexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Luggen M, Sheffer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthr Rheum. 1992;35:498–502.
   PubMed Web of Science ®Google Scholar
• Haggerty HG, Abbott MA, Reilly TP, DeVona DA, Gleason CR, Tay L, et al. Evaluation of immunogenicity of the T cell costi-mulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol. 2007;34:2365–73.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Pre-liminary definition of improvement in rheumatoid arthritis. Arthr Rheum. 1995;38:727–35.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthr Rheum. 1998;41:1564–70.
   Google Scholar
• Ma Y, Lin BR, Lin B, Hou S, Qian WZ, Li J, et al. Pharmacoki-netics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin. 2009;30:364–71.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36:736–42.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135:3172–7.
   PubMed Web of Science ®Google Scholar
• Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Grif-fiths I, et al. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radio-graphic progression in a longitudinal observational cohort at 8 years follow up. Arthr Res Ther. 2012;14:R30.
   Google Scholar
• Takeuchi T, Abe T, Yamamoto A, Miyasaka N. New biologics for rheumatoid arthritis in Japan. A multi-center, randomized, double-blind, controlled, dose-response study of abatacept (BMS-188667) in Japanese active rheumatoid arthritis (RA) patients with an inadequate response to methotrexate [abstract]. Mod Rheumatol. 2009;19(Suppl):S32.
   Google Scholar